JP2017519028A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519028A5
JP2017519028A5 JP2016575073A JP2016575073A JP2017519028A5 JP 2017519028 A5 JP2017519028 A5 JP 2017519028A5 JP 2016575073 A JP2016575073 A JP 2016575073A JP 2016575073 A JP2016575073 A JP 2016575073A JP 2017519028 A5 JP2017519028 A5 JP 2017519028A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
agent according
severe hypertriglyceridemia
compound
methylphenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016575073A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519028A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/037596 external-priority patent/WO2015200580A1/en
Publication of JP2017519028A publication Critical patent/JP2017519028A/ja
Publication of JP2017519028A5 publication Critical patent/JP2017519028A5/ja
Withdrawn legal-status Critical Current

Links

JP2016575073A 2014-06-26 2015-06-25 重度の高トリグリセリド血症の処置 Withdrawn JP2017519028A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462017444P 2014-06-26 2014-06-26
US62/017,444 2014-06-26
PCT/US2015/037596 WO2015200580A1 (en) 2014-06-26 2015-06-25 Treatment of severe hypertriglyceridemia

Publications (2)

Publication Number Publication Date
JP2017519028A JP2017519028A (ja) 2017-07-13
JP2017519028A5 true JP2017519028A5 (enExample) 2018-08-02

Family

ID=53511030

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016575073A Withdrawn JP2017519028A (ja) 2014-06-26 2015-06-25 重度の高トリグリセリド血症の処置

Country Status (16)

Country Link
US (1) US20150374649A1 (enExample)
EP (1) EP3160458A1 (enExample)
JP (1) JP2017519028A (enExample)
KR (1) KR20170020514A (enExample)
CN (1) CN106470675A (enExample)
AU (1) AU2015279905A1 (enExample)
BR (1) BR112016028918A2 (enExample)
CA (1) CA2951280A1 (enExample)
CL (1) CL2016003290A1 (enExample)
EA (1) EA201790091A1 (enExample)
HK (1) HK1231380A1 (enExample)
IL (1) IL249757A0 (enExample)
MX (1) MX2016017081A (enExample)
PH (1) PH12016502415A1 (enExample)
SG (1) SG11201610243YA (enExample)
WO (1) WO2015200580A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
RS57970B1 (sr) 2014-03-20 2019-01-31 Cymabay Therapeutics Inc Tretman intrahepatičkih holestatskih oboljenja
KR102374499B1 (ko) 2014-04-11 2022-03-14 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash 의 치료
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US20190224169A1 (en) * 2017-12-21 2019-07-25 Kowa Company, Ltd. Methods of Treatment of Hypertriglyceridemia
US20210145774A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
WO2021097034A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042478A2 (en) 2003-09-19 2005-05-12 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
NZ602125A (en) * 2010-03-30 2014-01-31 Novartis Ag Uses of dgat1 inhibitors

Similar Documents

Publication Publication Date Title
JP2017519028A5 (enExample)
CN104981253B (zh) 固溶体组合物及其在慢性炎症中的用途
JP2017513836A5 (enExample)
JP7053478B2 (ja) Fxrアゴニストを使用するための方法
CN105120872B (zh) 包含15-hepe的组合物以及其使用方法
JP2013521310A5 (enExample)
JP2015511638A5 (enExample)
JP2009530398A5 (enExample)
JP2018162255A5 (enExample)
JP2016538277A5 (enExample)
JP2018505158A5 (enExample)
JP2016538248A5 (enExample)
JP2015038155A5 (enExample)
JP2014505107A5 (enExample)
JP2017508817A5 (enExample)
JP2022031813A (ja) 15-hepeを含む組成物、およびそれを用いて線維症を処置または防止する方法
JP2016511753A5 (enExample)
JP2019520344A5 (enExample)
IL318963A (en) Compositions comprising 15-hydroxy-eicosapentaenoic acid and methods of using them
JP2015522603A5 (enExample)
JP2016508996A5 (enExample)
JP2010510229A (ja) 炎症性腸疾患のための治療方法
RU2019113150A (ru) Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения
JP2017519028A (ja) 重度の高トリグリセリド血症の処置
JP2017528473A5 (enExample)